Search

Boston Scientific Corp.

Gesloten

SectorGezondheidszorg

51.81 0.12

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

51.68

Max

52.75

Belangrijke statistieken

By Trading Economics

Inkomsten

-437M

904M

Verkoop

239M

5.4B

K/W

Sectorgemiddelde

19.945

57.002

EPS

0.86

Winstmarge

16.612

Werknemers

59,000

EBITDA

-214M

1.4B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+20.41% upside

Dividenden

By Acuity

Volgende Winsten

28 okt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

5.5B

73B

Vorige openingsprijs

51.69

Vorige sluitingsprijs

51.81

Nieuwssentiment

By Acuity

41%

59%

144 / 340 Rangschikking in Healthcare

Boston Scientific Corp. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 aug 2026, 23:01 UTC

Boston Scientific Corp shares are higher in after-market trading, continuing a trend of six consecutive sessions finishing higher. No specific news was identified.

13 aug 2026, 23:01 UTC

Social Media

Boston Scientific shares are higher in after-market trading, buoyed by social media discussions of the CEO's $9 million stock purchase amid a significant year-to-date decline.

12 aug 2026, 23:06 UTC

Boston Scientific Corp shares are modestly higher in after-market trading. The stock remains significantly above its 20-day moving average.

11 aug 2026, 23:41 UTC

Boston Scientific Corp shares are lower in after-market trading, showing unusual volatility and reflecting a broader trend of weakness since Tuesday's close.

10 aug 2026, 23:06 UTC

Boston Scientific shares are trading higher in after-market hours, amid mixed market sentiment influenced by geopolitical tensions, particularly concerning the Strait of Hormuz.

8 aug 2026, 00:01 UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting gains since Friday's close and remaining above their 20-day moving average.

7 aug 2026, 23:21 UTC

Boston Scientific shares are higher in after-market hours following a Labor Department report showing a decline in non-farm payroll employment, reducing interest rate hike expectations.

6 aug 2026, 23:01 UTC

Boston Scientific Corp shares are higher during after-market hours, reflecting a generally strong performance backdrop amid resilient labor market data.

5 aug 2026, 23:02 UTC

Social Media
News

Boston Scientific Corp shares rose in after-market trading following CEO Mahoney's purchase of 186,240 shares at an average price of $48.33.

4 aug 2026, 19:36 UTC

News

Boston Scientific shares are higher, supported by strong organic revenue growth and rising free cash flow margin, despite recent economic data pressures.

3 aug 2026, 23:01 UTC

Boston Scientific Corp shares are higher in after-market hours, reflecting positive momentum. Broader economic news shows increased growth in the manufacturing sector.

31 jul 2026, 22:52 UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting positive market sentiment from strong earnings by major tech companies.

30 jul 2026, 23:51 UTC

News

Boston Scientific shares are higher in after-market trading following UBS's Buy rating and a price target adjustment to $67 amid Penumbra's results.

29 jul 2026, 23:51 UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting broader market gains. No specific news has been identified to explain the movement.

28 jul 2026, 23:52 UTC

Boston Scientific Corp shares are higher in after-market hours, reflecting a steady increase since Tuesday's close despite broader market concerns, particularly in Asia.

27 jul 2026, 23:02 UTC

News
Social Media

Boston Scientific plans a restructuring with pre-tax charges of $700 million to $800 million, leading shares lower in after-market hours.

25 jul 2026, 00:01 UTC

News

Boston Scientific shares are higher in after-market hours despite a safety alert from the FDA regarding its ENROUTE Transcarotid Neuroprotection System catheters.

24 jul 2026, 23:01 UTC

News

Boston Scientific shares are higher in after-market hours despite a safety alert from the FDA regarding its ENROUTE Transcarotid Neuroprotection System catheters.

22 jul 2026, 20:06 UTC

Correlated Moves

Boston Scientific reported first-quarter adjusted EPS of $0.43, missing estimates. Shares are trading lower amid cautious market sentiment and Stryker's decline.

21 jul 2026, 23:06 UTC

Boston Scientific Corp shares are higher in after-hours trading, reflecting a modest uptick following Tuesday's close. The stock remains below its 20-day moving average.

20 jul 2026, 23:01 UTC

Boston Scientific shares are higher in after-market trading, reflecting notable strength since Monday's close, despite no specific news driving the movement.

Peer Vergelijking

Prijswijziging

Boston Scientific Corp. Prognose

Koersdoel

By TipRanks

20.41% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 62.41 USD  20.41%

Hoogste 89 USD

Laagste 50 USD

Gebaseerd op 24 Wall Street-analisten die 12-maands prijsdoelen bieden voor Boston Scientific Corp. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

24 ratings

21

Buy

3

Hold

0

Sell

Sentiment

By Acuity

144 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat